Also, they were less likely to be prescribed combinations of oral blood glucose lowering drugs, dipeptidyl peptidase-4, and exenatide/liraglutide for non-insulin-dependent diabetes mellitus. This evidence concerns the gene DPP4 and type 1 diabetes mellitus.